Item 1 Comment:
This Amendment No. 3 ("Amendment No. 3"), is filed with respect to the shares of common stock, $0.001 par value per share (the "Common Stock"), of Perspective Therapeutics, Inc., a Delaware corporation (the "Issuer"). This Amendment No. 3 amends and supplements the initial statement on Schedule 13D filed by Lantheus Alpha Therapy, LLC, a Delaware limited liability company ("Lantheus Alpha") and Lantheus Holdings, Inc., a Delaware corporation ("Lantheus Holdings" and, each of Lantheus Alpha, Lantheus Holdings and Lantheus Medical Imaging, Inc., a Delware corporation, referred to herein as "Lantheus Medical", a "Reporting Person" and, collectively, the "Reporting Persons") on February 1, 2024, as amended by Amendment No. 1 filed by Lantheus Alpha and Lantheus Holdings on March 8, 2024 and Amendment No. 2 filed by the Reporting Persons on September 4, 2026 (together, the "Original Statement" and, as amended by this Amendment No. 3, the "Statement"). Except as specifically provided herein, this Amendment No. 3 does not modify any of the information previously reported in the Original Statement. Capitalized terms used but not defined in this Amendment No. 3 shall have the meanings ascribed to them in the Original Statement. |
| (a) | Item 5(a) of the Original Statement is hereby amended and restated in its entirety as follows:
The percentage of beneficial ownership reported in this Item 5, and on each Reporting Person's cover page to this Statement, is based upon 114,151,663 shares of the Issuer's Common Stock issued and outstanding as of August 5, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026. All of the shares of Common Stock reported herein, and on each Reporting Person's cover page to this statement, are as of September 22, 2026.
The cover pages to this Statement are incorporated by reference in their entirety into this Statement. The number of shares of Common Stock disclosed in this Statement have been adjusted to reflect the Reverse Stock Split. |
| (b) | Item 5(b) of the Original Statement is hereby amended and restated in its entirety as follows:
Each Reporting Person beneficially owns an aggregate of 8,739,011 shares of Common Stock. This represents an aggregate beneficial ownership of 7.7% of the Common Stock. Shares reported as beneficially owned represent shares directly held by Lantheus Alpha, a wholly owned direct subsidiary of Lantheus Medical. Lantheus Medical is the sole member of Lantheus Alpha and a wholly-owned subsidiary of Lantheus Holdings. Lantheus Holdings, Lantheus Medical and Lantheus Alpha may each be deemed to have shared voting and dispositive power over all of the shares of Common Stock held by Lantheus Alpha.
To the best knowledge of each of the Reporting Persons, none of the individuals listed on Schedule A to this Statement beneficially owns any of the Issuer's Common Stock. |
| (c) | Item 5(c) of the Original Statement is hereby supplemented as follows:
On September 4, 2026, September 8, 2026, September 9, 2026, September 14, 2026, September 18, 2026, September 21, 2026 and September 22, 2026, Lantheus Alpha sold 167,149, 92,442, 65,500, 13,450, 750,000, 215,974 and 1,396,987 shares of Common Stock, respectively, on the open market for an average sales price per share of $3.1472, $3.133, $3.0098, $2.9531, $2.85, $2.9645 and $2.8976, respectively. Except as otherwise specified in this Statement, none of the Reporting Persons nor, to the best knowledge of the Reporting Persons, any of the persons set forth on Schedule A to this Statement, has engaged in any transaction in the Common Stock during the past 60 days. |
